article thumbnail

Post-COVID-19 cognitive impairment: a new target for drug development?

Drug Discovery World

Dr Paula Moran, Dr Kiri Granger, Dr J Mark Treherne , and Dr Jenny Barnett explore the effects of long Covid-19 symptoms and what the opportunities are for drug developers working to treat post-Covid-19 cognitive impairment. These may provide an opportunity for treatment for post-Covid-19 cognitive impairment.

article thumbnail

Key Challenges of Specialty Pharma Drug Development Project Management

thought leadership

Specialty pharma companies are focused on developing drugs for niche markets, such as rare diseases , cancer, and other complex conditions. These drugs often require significant investment in research and development, and their development requires careful project management.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Focus on core competencies : By outsourcing trial management to CROs, pharmaceutical companies and research institutions can concentrate on drug development and scientific innovation, rather than administrative tasks. Their ability to adapt to evolving regulations and industry standards reduces the likelihood of costly setbacks.

article thumbnail

SLAS2024 speaker update: How tech is reducing failure rates in clinical trials

Drug Discovery World

Dr Bentwich will present on ‘ How artificial intelligence and patient-on-a-chip are improving drug development ’ on Tuesday 6 February at 3pm. His presentation will explore the impact of Quris-AI’s Bio-AI platform in the field of drug development.

article thumbnail

Collaboration to develop AI modules for biotherapeutics 

Drug Discovery World

Our collaboration with BioMap further underscores Sanofi’s commitment to becoming the first pharma company powered by AI at scale.” The post Collaboration to develop AI modules for biotherapeutics appeared first on Drug Discovery World (DDW).

article thumbnail

Lessons from Monte Carlo Models: Why Drug Development is Hard

DrugBaron

But not everyone in drug development is playing this game. So what does the game look like to a late-stage investor or a pharma company head of R&D thinking about portfolio prioritisation? No wonder investing in drug development is so hard! But how do you know which game you are playing?

article thumbnail

Oncology Development Programme will accelerate cancer drug discovery

Drug Discovery World

The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. . ODP2 is seeking applications from academics and early-stage companies with a defined oncology-focused innovation.